Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 23 for:    gamaleya
Previous Study | Return to List | Next Study

Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03638830
Recruitment Status : Recruiting
First Posted : August 20, 2018
Last Update Posted : November 8, 2019
Sponsor:
Collaborator:
Acellena Contract Drug Research and Development
Information provided by (Responsible Party):
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

Brief Summary:
This study is planned to evaluate the safety and efficacy of the drug Ftortiazinon in combination with the drug Maxipime® in comparison with placebo in combination with the drug Maxipime® in the treatment of hospitalized adult patients with complicated urinary tract infections caused by P. aeruginosa.

Condition or disease Intervention/treatment Phase
Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa Pseudomonas Aeruginosa Pseudomonas Infections Urinary Tract Infections Drug: Ftortiazinon (tablets 300 mg) 1/2 dose +placebo+ Maxipim Drug: Ftortiazinon (tablets 300 mg) full dose + Maxipim Other: placebo+Maxipim Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 777 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: randomized, blind, placebo-controlled study
Masking: Double (Participant, Investigator)
Masking Description:

In order to minimize subjectivity, block randomization will be carried out in treatment groups without stratification in the center. Randomization will be carried out by the method of envelopes.

To minimize the subjectivity of clinical study of the efficacy and safety of the drug "Ftortiazinon" will be conducted with the use of a placebo, which will not differ in appearance, shape, color, and will fully simulate the investigated product.

To distribute the drug to patients, taking into account the need to observe the blinding, a special authorized person (an unblided research pharmacist) will be appointed in each medical organization.

Primary Purpose: Treatment
Official Title: Randomized, Blind, Placebo-controlled Study to Evaluate Safety and Efficacy of Ftortiazinon in Combination With Maxipime®, in Comparison With Placebo in Combination With Maxipime®, in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa
Actual Study Start Date : October 17, 2018
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : January 31, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group 1
Ftortiazinon tablets 300 mg (FSBI "N.F. Gamaleya NRCEM" of the Ministry of Health of the Russian Federation)1/2 dose + placebo+ Maxipime®
Drug: Ftortiazinon (tablets 300 mg) 1/2 dose +placebo+ Maxipim
Ftortiazinon tablets 300 mg (FSBI "N.F. Gamaleya NRCEM" of the Ministry of Health of the Russian Federation)+placebo

Experimental: Group 2
Ftortiazinon tablets 300 mg (FSBI "N.F. Gamaleya NRCEM" of the Ministry of Health of the Russian Federation) full dose + Maxipime®
Drug: Ftortiazinon (tablets 300 mg) full dose + Maxipim
Ftortiazinon tablets 300 mg (FSBI "N.F. Gamaleya NRCEM" of the Ministry of Health of the Russian Federation)

Placebo Comparator: Group 3
placebo (like full dose) in combination with the drug Maxipime®
Other: placebo+Maxipim
placebo




Primary Outcome Measures :
  1. clinical cure and microbiological eradication [ Time Frame: through the whole study, an average of 90 days ]
    proportion of patients with overall positive effect


Secondary Outcome Measures :
  1. proportion of patients with clinical cure response [ Time Frame: through the whole study, an average of 90 days ]
    proportion of patients with clinical cure response in the patient population treated with the drugs specified in the Study Protocol, i.e. corresponding to the MITT criterion, in the group of patients with the isolated pathogen P. aeruginosa in urine at baseline, i.e. corresponding to the m-MITT criterion, patient population suitable for clinical evaluation (CE), and patient population suitable for microbiological evaluation (ME)

  2. proportion of patients with response in the form of microbiological eradication [ Time Frame: through the whole study, an average of 90 days ]
    proportion of patients with response in the form of microbiological eradication in the m-MITT and ME populations during medical and pedagogical observations;

  3. microbiological eradication [ Time Frame: day 7 ]
    microbiological eradication for each selected pathogen in the m-MITT and ME populations during medical observations

  4. number of patients with treatment response as clinical cure [ Time Frame: day 7 ]
    relative number of patients with treatment response as clinical cure in the MITT and m-MITT populations

  5. Number of Participants With Adverse Events [ Time Frame: through the whole study, an average of 90 days ]
    Determination of Number of Participants With Adverse Events

  6. Number of Participants With Serious Adverse Events [ Time Frame: through the whole study, an average of 90 days ]
    Determination of Number of Participants With Serious Adverse Events

  7. Number of Participants with Solicited Local and Systemic Adverse Events [ Time Frame: through the whole study, an average of 90 days ]
    Determination of Number of Participants with Solicited Local and Systemic Adverse Events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 1. The ability to understand the requirements of the study participants, to give written consent to participate in the study (including the use and transfer of information about the patient's health related to the study) and the implementation of the procedures provided by the Study Protocol.

    2. Availability of the patient's written consent to participate in the study according to the current legislation.

    3. Male or female participants must be ≥18 and ≤80 years of age. 4. It is expected that patient's treatment of complicated UTI will require hospitalization and the use of antibiotic therapy.

    5. Suspected or documented complicated UTI as defined below and subject to the mandatory presence of one or more of the risks associated with the complicated UTI listed below:

Complicated urinary tract infection (complicated UTI):

• presence of at least 2 of the following signs or symptoms:

  • chills, tremors, or body temperature increases associated with fever (body temperature of 38ºC) (fever documented by a medical professional within 24 hours prior to screening);
  • nausea or vomiting within 24 hours prior to screening;
  • dysuria, frequent urination or urgent need to urinate;
  • pain in the lower abdomen;
  • acute pain in the side (occurred within 7 days prior to randomization) or pain in the region of the rib-vertebral angle during physical examination.

    • leukocyturia in a urine sample (presence of at least one of the following signs):

  • positive reaction to leukocyte esterase based on the results of the common urine examination;
  • number of leukocytes ≥ 10 cells/mm3 in non-centrifuged urine sample;
  • number of leukocytes ≥ 10 cells / per HPF in the urine sediment. 6. At least one of the following associated risks: • periodic bladder catheterization or the presence of a permanent bladder catheter, ureters (ureter stent), kidneys (nephrostoma) (catheters installed more than 24 hours prior to screening should be removed or replaced prior to collection of an urine sample for analysis and sowing, unless removal or replacement is considered unsafe or contraindicated);

    • presence of known functional or anatomical abnormalities in the urinary system, including malformations, neurogenic bladder, presence of residual urine volume ≥ 100 ml, stricture after surgery and/or malformations of the urinary tract, separate drainage of the kidney and/or bilateral nephrostomy tubes;
    • complete or partial obstructive uropathy (e.g. nephrolithiasis, tumor, fibrosis, urethral stricture, cystolithiasis) that is expected to be subjected to therapeutic or surgical treatment during treatment with the drug under study (until the end of therapy);
    • azotemia defined as blood urea nitrogen level (BUN) > 20 mg/dl, blood urea level > 42.8 mg/dl, or serum creatinine > 1.4 mg/dl due to known kidney disease in anamnesis;
    • chronic urinary retention in men, e.g. due to the previously diagnosed benign prostatic hypertrophy.

      7. Obtaining the patient's initial urine sample for sowing within 24 hours before randomization (patients can be randomized in this study and start therapy with the drug under study before the results of the initial urine culture become known to the researcher).

      8. A reasonable assumption that any installed urinary device (e.g., nephrostomy catheter, permanent stents) will be surgically removed or replaced before or within 24 hours of randomization (temporary catheters that were installed more than 24 hours before screening should be removed or replaced before urine sample collection for analysis and sowing).

      9. Recurrent complicated urinary tract infection within 12 months before the study (presence of complicated urinary tract infection in anamnesis with a frequency of more than twice per year).

      10. Suspected infection caused by multiresistant strains of P. aeruginosa, inefficiency of previous treatment.

      11. High risk of complicated UTI caused by P. aeruginosa (e.g. pseudomonal complicated UTI in anamnesis, therapy of 20 mg or more with prednisone or equivalent steroid and other risk factors that are taken into account by the researcher.

      12. Prognostic life expectancy of the patient with effective antibiotic therapy and proper maintenance treatment is estimated by the researcher to be at least 6 months.

      13. Women who capable of childbirth (i.e. not in menopause and not surgically sterilized) should have a negative pregnancy test result before randomization. Participants in the study who are capable of procreation, or sexual partners of participants who are capable of childbirth, should agree to the continued use of a highly effective method of contraception from the beginning of screening to the end of the study (medical and pedagogical observations) (highly effective methods of contraception include hormonal implants, plasters, injectable hormones, oral hormonal contraceptives, intrauterine systems, approved cervical ring, prior bilateral ovariectomy, prior hysterectomy, previous bilateral tubal ligation, true abstinence from sexual activity (if confirmed by the researcher), or vasectomy with a partner.

      14. Male participants of the study will need to use condoms with spermicide during sexual intercourse during screening up to the end of the study in case of possible and even existing pregnancy of the sexual partner.

Exclusion Criteria:

  • 1. Presence of any known or suspected disease, or condition that may distort the assessment effectiveness, including, but not limited to, the following:

    • perinephral abscess;
    • corticomedullary kidney abscess;
    • any history of pelvic or urinary tract injury within 30 days prior to the study;
    • polycystic kidney disease;
    • chronic vesicoureteral reflux;
    • prior or planned kidney transplantation;
    • dialysis patients, including those under hemodialysis, peritoneal dialysis or continuous venovenous hemofiltration (CVVH);
    • previous or planned cystectomy or surgery on the loop of ileum;
    • presence of a known or suspected infection that is caused by fungi (e.g. candiduria) or mycobacteria (e.g. urogenital tuberculosis).

      2. Presence of suspected or confirmed acute bacterial prostatitis, orchitis, epididymitis or chronic bacterial prostatitis determined by anamnesis and/or general medical examination.

      3. Macrogematuria requiring treatment other than administration of the drug under study or removal, or replacement of the urinary catheter.

      4. Surgery on the urinary tract within 7 days before randomization, or surgery on the urinary tract planned during the period of study (except surgical intervention necessary to remove the obstruction or placement of the stent or holding of a nephrostomy until the end of treatment (medical and pedagogical observations).

      5. Renal function in screening evaluated by creatinine clearance as < 50 ml / min using the Cocroft-Gault formula and serum creatinine values obtained in a local laboratory.

      6. Source of infection diagnosed within 7 days prior to randomization with known extra-renal origin, such as endocarditis, osteomyelitis, abscess, burn urinary tract infection; meningitis or pneumonia.

      7. Any signs of sepsis, including shock or deep arterial hypotension, which is defined as SBP < 90 mm Hg or a pressure reduction of > 40 mm Hg from the initial level (if known) not reacting to the load with a liquid.

      8. Pregnant or breastfeeding women. 9. Established epileptic syndrome requiring ongoing treatment with an anticonvulsant drug, which will not allow the patient to comply with the treatment regimen according to the Study Protocol. Patients with a history of epilepsy or those receiving stable therapy (i.e. unchanged therapy for 30 days) with a well-controlled epileptic syndrome (i.e. with no recurrence within the last 30 days) may be considered for admission to the study.

      10. Treatment with antitumor chemotherapeutic drugs, treatment with immunosuppressive therapy for transplantation, or drugs preventing rejection of the transplant within 30 days prior to randomization.

      11. Signs of severe disease or liver dysfunction, including confirmed viral hepatitis or hepatic encephalopathy.

      12. AST or ALT > 3 x ULN (upper limit of normal) or total bilirubin > 1.5 x ULN at screening.

      13. Administration of any long-acting systemic antibiotic (i.e. with a frequency of less than once per day) for less than 12 hours prior to randomization.

However, the following patients may be included:

• who have received antimicrobial therapy for > 24 hours and have not responded to treatment (i.e. signs and symptoms have worsened) and have documented complicated UTIs caused by pathogen microorganisms resistant to previous therapy;

  • who developed signs and symptoms of complicated UTI in the administration of systemic antibiotics for other indications, including antimicrobial prophylaxis against recurrent UTI;
  • who received short-acting systemic antibiotic therapy (i.e. with frequency of administration more than once per day) for 24 hours before randomization, but not less than 12 hours prior to randomization.

    14. Need for additional systemic antimicrobial therapy at the time of randomization (including antibiotic, antifungal therapy), other than treatment with the drug under study, except for a single oral administration of any antifungal drug for the treatment of vaginal candidiasis.

    15. Likelihood of the need for an antibiotic to prevent complicated UTI during patient participation in the study (from randomization to medical and pedagogical observations).

    16. Impossibility of removal or replacement of temporary catheters installed in more than 24 hours prior to the screening from the perspective of evaluating the safety of the patient or presence of contraindications to manipulation (temporary catheters installed more than 24 hours prior to the screening should be removed or replaced prior to collecting the urine sample for analysis and sowing).

    17. History of HIV infection. 18. Presence of significant immunodeficiency or immune deficiency, including hematologic malignant disease, bone marrow transplantation or receiving immunosuppressive therapy, such as chemotherapy for cancer, administration of drugs to prevent graft rejection and long-term use of systemic corticosteroids (equivalent to the use of prednisone or equivalent systemic drug at a dose ≥ 20 mg/day for ≥ 2 weeks).

    19. Presence of neutropenia (absolute number of neutrophils < 1000/mm3) based on the results of the screening analysis in the central laboratory.

    20. Presence of thrombocytopenia (especially in patients diagnosed with disseminated intravascular coagulation or risk of serious bleeding) 50,000 platelets/mm3 confirmed on the basis of indicators obtained in the central laboratory during screening.

    21. Lactose intolerance, lactose deficiency or glucose-galactose absorption, severe hypersensitivity or allergic reaction to β-lactam antibiotics, L-arginine, local anesthetics, antiarrhythmics or to the components of the drug in anamnesis.

    22. Presence of any contraindications to the use of β-lactam antibiotics (cephalosporins, penicillins, carbapenems or monobactams), to administration of auxiliary substances that are part of the relevant dosage forms.

    23. Participation in another clinical trial using the drug or device under study for the last 90 days prior to randomization.

    24. Inability or unwillingness to comply with the requirements of the Study Protocol.

    25. Any patients previously randomized into this study.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03638830


Contacts
Layout table for location contacts
Contact: Nailya Zigangirova, PhD 193 30 60 ext 499 zigangirova@mail.ru

Locations
Layout table for location information
Russian Federation
Road Clinical Hospital of Open Joint Stock Company "Russian Railways Recruiting
Saint Petersburg, Russian Federation
Contact: Victor Shunkov         
St. Petersburg state budgetary institution of health care " City hospital № 26" Recruiting
Saint Petersburg, Russian Federation
Contact: Alexander Mangushlo         
Baltic Medicine Recruiting
Saint-Petersburg, Russian Federation
Contact: Maksim Bushara, MD         
Scientific and Research Center "Eco-Safety" Recruiting
Saint-Petersburg, Russian Federation
Contact: Dmitry Gorelov         
Vsevolozhsk Clinical Interdistrict Hospital Recruiting
Vsevolozhsk, Russian Federation
Contact: Elena Matevosyan         
Sponsors and Collaborators
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Acellena Contract Drug Research and Development
Investigators
Layout table for investigator information
Principal Investigator: Victor Shunkov, MD, PhD Road Clinical Hospital of Open Joint Stock Company "Russian Railways
Principal Investigator: Alexander Shvets, MD Saint-Petersburg Clinical Hospital of the Russian Academy of Sciences
Principal Investigator: Dmitry Gorelov, MD Scientific and Research Center "Eco-Safety"
Principal Investigator: Lyudmila Kulagina, MD Republican Clinical Hospital of the Ministry of Health of the Republic of Tatarstan
Principal Investigator: Elena Matevosyan, MD Vsevolozhsk Clinical Interdistrict Hospital
Principal Investigator: Maria Mozheyko, MD Yaroslavl Regional Clinical Hospital for Military Veterans
Principal Investigator: Lev Sinelnikov, MD S.M. Kirov Military Medical Academy
Principal Investigator: Maksim Bushara, MD Baltic Medicine
Principal Investigator: Ashot Yesayan, MD Saint-Petersburg State Budgetary Healthcare Institution "City Clinical Hospital No. 31"
Principal Investigator: Alexander Mangushlo, MD St. Petersburg state budgetary institution of health care " City hospital № 26"
Principal Investigator: Andrey Gorelov, MD St. Petersburg state budgetary institution of health care " city Pokrovskaya hospital"
Principal Investigator: Grigory Arutunov, MD Pirogov Russian National Research Medical University
Principal Investigator: Ivan Palagin, MD Smolensk regional clinical hospital
Principal Investigator: Igor Shormanov, MD State Autonomous healthcare institution of Yaroslavl region Clinical hospital № 9
Layout table for additonal information
Responsible Party: Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
ClinicalTrials.gov Identifier: NCT03638830    
Other Study ID Numbers: 04-FT-2018
First Posted: August 20, 2018    Key Record Dates
Last Update Posted: November 8, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation:
Pseudomonas Aeruginosa
antibiotic resistance
factors of pathogenicity of bacteria
the system of secretion of type III pathogenic bacteria
Pseudomonas Infections
Urinary Tract Infections
Additional relevant MeSH terms:
Layout table for MeSH terms
Infection
Communicable Diseases
Urinary Tract Infections
Pseudomonas Infections
Urologic Diseases
Gram-Negative Bacterial Infections
Bacterial Infections